Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Eric Venker, an officer of Roivant Sciences Ltd. (ROIV), reported a proposed sale of 200,000 common shares with an aggregate market value of $7,317,764.00. The shares are to be sold pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026. He also reported four sales during the preceding three months, dated August 20, August 28, September 30, and October 20, 2026.
Roivant Sciences Ltd. director Oren Ilan received an award of 810 Common Shares on October 23, 2026, under the issuer’s Non-Employee Director Compensation Plan. The award was fully vested as of the grant date. Oren Ilan directly held 124,490 Common Shares following the transaction.
Roivant Sciences Ltd. director Melissa B. Epperly received a fully vested award of 513 Common Shares on October 23, 2026, under the company’s Non-Employee Director Compensation Plan. On the same date, the issuer net settled 116 shares to satisfy tax-withholding obligations connected with vesting and settlement; the reported transaction price was $36.49 per share. No Rule 10b5-1 plan is reported.
Roivant Sciences Ltd. (ROIV) director James C. Momtazee received an award of 383 Common Shares under the Non-Employee Director Compensation Plan on October 23, 2026; the award was fully vested as of the grant date. On that date, the issuer net-settled 77 Common Shares to satisfy applicable tax withholding obligations, with a reported price of $36.49 per share.
Roivant Sciences Ltd. reported that BlackRock, Inc. beneficially owned 59,285,183 common shares, or 8.2% of the class, as of September 30, 2026. BlackRock reported sole voting power over 56,524,198 shares and sole dispositive power over 59,285,183 shares, with no shared voting or dispositive power.
Roivant Sciences Ltd. President and Immunovant CEO Eric Venker reported sales of 185,856 Common Shares at a weighted average price of $35.09 and 14,144 Common Shares at a weighted average price of $35.42 on October 20, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted June 30, 2026. The first group sold at prices ranging from $34.38 to $35.38, inclusive; the second ranged from $35.39 to $35.51, inclusive.
Roivant Sciences Ltd. announced positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis, studied by its subsidiary Priovant Therapeutics. Brepocitinib met the primary endpoint in both CLARITY-1 and CLARITY-2. The company also reported statistically significant and clinically meaningful benefit on all key secondary endpoints, including sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning.
Those results were achieved despite a substantially more aggressive steroid taper than in precedent NIU trials. The release also reports consistent benefits on preventing treatment failure across intermediate, posterior and panuveitis; patients with and without prior TNFi experience; and multiple etiologies, including idiopathic disease, birdshot chorioretinopathy and sarcoidosis.
Roivant Sciences Ltd. President & CIO and director Mayukh Sukhatme had 19,976 common shares withheld on October 16, 2026, through the issuer’s net settlement of performance restricted stock units to satisfy tax-withholding obligations after performance and service conditions were met. The reported price was $33.53 per share, and his reported direct holdings following the transaction were 18,563,884 common shares.
Additional PSUs that have satisfied both conditions will be settled in future installments. Shares issued on settlement, excluding those withheld for taxes, remain subject to a two-year holding period measured from satisfaction of the service condition.
Roivant Sciences Ltd. CEO and director Matthew Gline had 34,638 common shares withheld on October 16, 2026, at $33.53 per share to satisfy tax withholding obligations in the issuer’s net settlement of performance restricted stock units (PSUs). The settlement followed achievement of both performance- and service-based vesting conditions; Gline directly held 16,549,136 common shares afterward. Common shares issued from the PSU settlement, excluding shares withheld for taxes, are subject to a two-year holding period measured from satisfaction of the service condition. Additional PSUs that have satisfied both conditions will be settled in future instalments under their terms.
Roivant Sciences Ltd. (ROIV) reports that its officer, Eric Venker, gave notice of a proposed sale of 200,000 common shares, with an aggregate market value of $7,023,513.39. The approximate sale date is October 20, 2026, through Rockefeller Financial LLC on NASDAQ. The sale is pursuant to a Rule 10b5-1 trading plan adopted by Venker on June 30, 2026.